Medy-Tox Inc. (086900.KQ)
KRW 124900.0
(-2.42%)
KRW 124900.0
(-2.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 32.69 Billion KRW | -47.12% |
| 2022 | 70.36 Billion KRW | 20.16% |
| 2021 | 51.39 Billion KRW | 378.23% |
| 2020 | -18.47 Billion KRW | -141.72% |
| 2019 | 44.27 Billion KRW | -56.26% |
| 2018 | 101.53 Billion KRW | 7.53% |
| 2017 | 95.23 Billion KRW | 17.79% |
| 2016 | 81.42 Billion KRW | 43.98% |
| 2015 | 55.97 Billion KRW | 4.61% |
| 2014 | 53.06 Billion KRW | 184.87% |
| 2013 | 18.62 Billion KRW | -0.89% |
| 2012 | 18.79 Billion KRW | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 3.92 Billion KRW | -46.8% |
| 2024 Q2 | 19.59 Billion KRW | 391.77% |
| 2023 Q2 | 13.03 Billion KRW | 154.23% |
| 2023 FY | - KRW | -47.12% |
| 2023 Q4 | 7.23 Billion KRW | 0.27% |
| 2023 Q1 | 5.12 Billion KRW | -74.3% |
| 2023 Q3 | 7.21 Billion KRW | -44.6% |
| 2022 Q3 | 18.19 Billion KRW | 27.11% |
| 2022 FY | - KRW | 20.16% |
| 2022 Q4 | 19.94 Billion KRW | 9.61% |
| 2022 Q2 | 14.31 Billion KRW | 51.58% |
| 2022 Q1 | 9.44 Billion KRW | 160.55% |
| 2021 FY | - KRW | 378.23% |
| 2021 Q1 | 115.87 Million KRW | 101.67% |
| 2021 Q2 | 9.06 Billion KRW | 7727.1% |
| 2021 Q3 | 38.59 Billion KRW | 325.51% |
| 2021 Q4 | 3.62 Billion KRW | -90.61% |
| 2020 Q3 | -6.75 Billion KRW | -1246.15% |
| 2020 Q4 | -6.93 Billion KRW | -2.64% |
| 2020 FY | - KRW | -141.72% |
| 2020 Q2 | 589.35 Million KRW | 110.97% |
| 2020 Q1 | -5.37 Billion KRW | -5278.94% |
| 2019 FY | - KRW | -56.26% |
| 2019 Q1 | 20.45 Billion KRW | -3.24% |
| 2019 Q2 | 15.59 Billion KRW | -23.76% |
| 2019 Q4 | -99.89 Million KRW | -101.27% |
| 2019 Q3 | 7.87 Billion KRW | -49.53% |
| 2018 Q4 | 21.14 Billion KRW | -7.71% |
| 2018 FY | - KRW | 7.53% |
| 2018 Q3 | 22.91 Billion KRW | -14.45% |
| 2018 Q2 | 26.78 Billion KRW | -12.76% |
| 2018 Q1 | 30.69 Billion KRW | 22.0% |
| 2017 Q3 | 19.13 Billion KRW | -32.04% |
| 2017 Q1 | 22.77 Billion KRW | -3.5% |
| 2017 Q2 | 28.16 Billion KRW | 23.67% |
| 2017 Q4 | 25.16 Billion KRW | 31.48% |
| 2017 FY | - KRW | 17.79% |
| 2016 Q4 | 23.59 Billion KRW | 24.11% |
| 2016 Q3 | 19.01 Billion KRW | -1.29% |
| 2016 Q2 | 19.26 Billion KRW | 6.73% |
| 2016 Q1 | 18.04 Billion KRW | 18.78% |
| 2016 FY | - KRW | 43.98% |
| 2015 Q2 | 14.72 Billion KRW | 21.82% |
| 2015 Q1 | 12.08 Billion KRW | 62.78% |
| 2015 Q4 | 15.19 Billion KRW | 12.5% |
| 2015 Q3 | 13.5 Billion KRW | -8.27% |
| 2015 FY | - KRW | 4.61% |
| 2014 Q1 | 8.22 Billion KRW | 78.11% |
| 2014 Q4 | 7.42 Billion KRW | -72.69% |
| 2014 Q2 | 10.22 Billion KRW | 24.21% |
| 2014 Q3 | 27.18 Billion KRW | 165.96% |
| 2014 FY | - KRW | 184.87% |
| 2013 Q2 | 5.95 Billion KRW | 69.44% |
| 2013 Q4 | 4.62 Billion KRW | 1.8% |
| 2013 FY | - KRW | -0.89% |
| 2013 Q1 | 3.51 Billion KRW | -2.36% |
| 2013 Q3 | 4.53 Billion KRW | -23.76% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q4 | 3.59 Billion KRW | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| HLB Co., Ltd. | -172.27 Billion KRW | 118.98% |
| iNtRON Biotechnology, Inc. | -6.23 Billion KRW | 624.458% |
| BINEX Co., Ltd. | 10.87 Billion KRW | -200.755% |
| Bioneer Corporation | 10.04 Billion KRW | -225.575% |
| Anterogen.Co.,Ltd. | -437.82 Million KRW | 7568.329% |
| MEDIPOST Co., Ltd. | -19.39 Billion KRW | 268.62% |
| CrystalGenomics, Inc. | -42.79 Billion KRW | 176.403% |
| Helixmith Co., Ltd | -53 Billion KRW | 161.69% |
| Chabiotech Co.,Ltd. | 70.08 Billion KRW | 53.347% |
| Peptron, Inc. | -12.65 Billion KRW | 358.473% |
| Amicogen, Inc. | 13.95 Billion KRW | -134.343% |
| Genexine, Inc. | -40.87 Billion KRW | 179.989% |
| HLB Therapeutics Co.,Ltd. | 8.22 Billion KRW | -297.325% |
| LegoChem Biosciences, Inc. | -71.38 Billion KRW | 145.806% |
| ALTEOGEN Inc. | 440.04 Million KRW | -7330.697% |
| PharmaResearch Co., Ltd. | 104.25 Billion KRW | 68.636% |
| SillaJen, Inc. | -17.35 Billion KRW | 288.435% |
| JETEMA, Co., Ltd. | 11 Billion KRW | -197.047% |
| OliX Pharmaceuticals,Inc | -11.13 Billion KRW | 393.651% |
| Genomictree Inc. | -6.33 Billion KRW | 616.409% |
| MedPacto, Inc. | -32.6 Billion KRW | 200.275% |
| D&D Pharmatech | -9.05 Billion KRW | 460.991% |
| EASY BIO,Inc. | 24.32 Billion KRW | -34.432% |
| GI Innovation, Inc. | -51.33 Billion KRW | 163.701% |